Status:
COMPLETED
B7-Family Score in Urothelial Carcinoma
Lead Sponsor:
Shanghai Zhongshan Hospital
Collaborating Sponsors:
Fudan University
Shanghai Jiao Tong University School of Medicine
Conditions:
Urothelial Carcinoma
Eligibility:
All Genders
Brief Summary
Immunotherapy has been found to confer substantial survival benefits to the patients with higher mutation burdens, which become the first biomarker approved by FDA in urothelial carcinoma (UC). Nevert...
Detailed Description
On the basis of established findings in the prognostic and functional properties of the three B7 family members, i.e., PD-L1, B7-H3, and B7-H4, we employed the IMVigor210 cohort as the discovery cohor...
Eligibility Criteria
Inclusion
- Patients with muscle-invasive bladder cancer receiving radical cystectomy have been included in this study.
Exclusion
- Patients with non-muscle invasive bladder cancer were not eligible in this study.
Key Trial Info
Start Date :
January 25 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 22 2022
Estimated Enrollment :
215 Patients enrolled
Trial Details
Trial ID
NCT06169904
Start Date
January 25 2012
End Date
November 22 2022
Last Update
December 14 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.